Marine-Bioeconomy

Large-scale cultivation and processing of macroalgae (seaweed) into sustainable biopolymers, animal feed additives, and biofuels, decoupling production from terrestrial land and freshwater.

Multispecies probiotic blends and microencapsulated Bacillus/Streptomyces strains manage shrimp and fish gut and pond-water microbiomes, controlling Vibrio-driven disease without antibiotics.

Capturing industrial CO2 emissions using microalgae to produce valuable biomass, biofuels, and bioplastics.

Geographic agglomerations of marine and coastal bio-industries — Iceland's 100% Fish cod-utilization cluster, Norway's GCE Ocean Technology, Maine's Bigelow Blue Biotech Studio and the NSF Seafood Engine, Qingdao's six provincial marine clusters and Xiamen Torch Group's marine park — that turn a coastal resource base into spinoff firms, byproduct upcycling and regional blue-economy growth, against a global ocean economy projected to double by 2030.

High-tech interventions including land-based farming and 3D printing to accelerate the growth and resilience of coral reefs.

The UN High Seas Treaty (BBNJ Agreement) entered into force in January 2026, creating the first legal regime for accessing and sharing benefits from marine genetic resources collected outside any nation's waters — turning deep-sea genomic prospecting from an unregulated commons into a treaty-governed pipeline running from Ocean Genome Legacy's biobank to PharmaMar's marine-derived oncology drugs.

Bioactive peptides, low-molecular-weight collagen and omega-3 recovered from fishery by-catch (heads, skin, bones) by enzymatic hydrolysis, tangential ultrafiltration and spray-drying — a circular-blue-economy stack for nutraceuticals, cosmeceuticals and functional food.

Cultivating microalgae to produce sustainable omega-3 oils and protein for aquafeed and human nutrition.

Microalgae-derived carotenoids — natural astaxanthin from Haematococcus pluvialis and beta-carotene from Dunaliella salina — produced as high-concentration oleoresins and supplement ingredients by dedicated cultivators in the USA, India, Austria and Iceland.

Microalgae-derived EPA and DHA omega-3 oils — from Crypthecodinium, Nannochloropsis and Schizochytrium — produced as vegan nutraceutical and infant-nutrition ingredients by DSM-Firmenich, Qualitas Health, Fermentalg and Kingdomway.

Moving fish farming into exposed, high-energy waters with submersible steel cages, autonomous vessel-farms and AI feeding, de-risked by NS 9415 cage hydrodynamics and integrated multi-trophic aquaculture (IMTA) to cut nitrogen load, under NOAA/EPA, EU EIA and China's deep-sea aquaculture programmes.

Plant-protein isolates, fermented mycoprotein and seaweed are extruded and 3D-structured into whole-cut and canned seafood substitutes — a route distinct from cell-cultured seafood (cultured-seafood), marine peptides (marine-peptides-nutraceuticals) and microalgal protein (microalgae-aquaculture), driven by 2026 scale-up milestones: Revo Foods' TASTE FACTORY in Vienna, BettaF!sh's cross-Atlantic acquisition by Bayou Best Foods, and Oshi's 3 million dollar raise.